Trial Profile
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 as a Single Agent in Patients With Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Modakafusp alfa (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms iinnovate-1
- Sponsors Takeda; Takeda Development Center Americas; Takeda Oncology
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results (n=37) assessing pharmacodynamic of Modakafusp Alfa in Patients with Relapsed and/or Refractory Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 21 Oct 2023 This trial has been discontinued in Germany according to European Clinical Trials Database record.